Neither MAOIs nor SSRIs are universally more effective than the other; effectiveness varies significantly by individual patient and specific condition. Both drug classes are established treatments for depression and anxiety, but they work through different mechanisms and suit different clinical situations.
SSRIs (selective serotonin reuptake inhibitors) are typically prescribed first because they have fewer drug and food interactions, simpler dosing, better tolerability for most patients, and a safer overdose profile. They're effective for depression, anxiety disorders, OCD, and PTSD.
MAOIs (monoamine oxidase inhibitors) can be remarkably effective, sometimes working when SSRIs haven't, particularly for treatment-resistant depression, atypical depression, and certain anxiety disorders. However, they require dietary restrictions (avoiding tyramine-containing foods), careful monitoring, and pose risks of serious interactions with other medications and substances.
Research shows individual response rates are comparable overall, but response patterns differ. Some patients achieve remission on SSRIs while others respond better to MAOIs. A minority of people with severe, treatment-resistant depression may find MAOIs superior when multiple SSRIs have failed.
Clinicians typically start with SSRIs due to their safety profile and convenience, then consider MAOIs for patients who don't respond adequately or experience intolerable side effects. The most effective antidepressant for any individual person is ultimately determined through careful treatment trials, not by class comparisons.